Spontaneous Intraventricular Hemorrhage: When Should Intraventricular tPA Be Considered?

Peter A. Abdelmalik, MD, PhD1 Wendy C. Ziai, MD, MPH1

1 Division of Neurosciences Critical Care, Departments of Neurology and Anesthesia and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Semin Respir Crit Care Med 2017;38:745–759.

Address for correspondence Wendy C. Ziai, MD, MPH, Division of Neurosciences Critical Care, Departments of Neurology, Anesthesia and Critical Care Medicine, The Johns Hopkins University School of Medicine, 600 N Wolfe St., Phipps 455, Baltimore, MD 21287 (e-mail: weziai@jhmi.edu).

Abstract

Spontaneous intracerebral hemorrhage (ICH) is the most common cause of intraventricular hemorrhage (IVH) in adults. Complicating approximately 40% of ICH cases, IVH adds to the morbidity and mortality of this often fatal form of stroke. It is also a severity factor that complicates subarachnoid hemorrhage and traumatic brain injury, along with other less common causes of intracranial bleeding. Medical and surgical interventions to date have focused on limiting ICH and IVH expansion, controlling intracranial pressure, and relieving obstructive hydrocephalus. The placement of an external ventricular drain (EVD) can achieve the latter two goals but has not demonstrated improvement in clinical outcomes beyond mortality reduction. More recently, intraventricular fibrinolysis, utilizing the EVD, has gained interest as a safe and potentially effective method to maintain catheter patency and facilitate hematoma removal. A recent phase III clinical trial evaluating the efficacy of intraventricular alteplase versus intraventricular saline showed a mortality benefit, but failed to meet the primary endpoint of significant functional improvement. However, planned subgroup analysis focusing on patients with IVH volume > 20 mL, and those with IVH removal > 85% suggest that significant functional benefits may be attainable with this therapy. The practice of intraventricular fibrinolysis for spontaneous IVH is not the standard of care; however, based on 20 years of experience, it meets thresholds as a safe intervention, and in those patients with a high burden of intraventricular blood, aggressive clearance may lead to improved quality of life in survivors of this morbid syndrome.

Keywords

► intracerebral hemorrhage
► intraventricular hemorrhage
► fibrinolysis
► thrombolysis
► hydrocephalus
► Graeb
► alteplase
► external ventricular drain
► ventriculostomy

Rare are the syndromes in modern medicine that can cause sudden death so rapid that it goes unexplained even after an extensive postmortem examination. Acute obstructive hydrocephalus—caused by a tumor, cyst, or, more commonly, intraventricular hemorrhage (IVH)—leads to a rapid increase in intracranial pressure (ICP), accompanied by autonomic dysfunction and rostrocaudal herniation of the brainstem which can potentially lead to a very rapid sudden death.1

Prior to the routine use of computed tomography (CT) scans of the head, IVH was classically diagnosed at autopsy, with evidence of extravasated blood obstructing the ventricular system. Because of the nature of this finding, it was felt that IVH was universally fatal. However, with modern neuroimaging, IVH has been characterized extensively and ranges from mild layering of blood, typically in the posterior horn of the lateral ventricle, to complete casting of all ventricles.2
IVH can be classified into two categories: primary IVH and secondary IVH. Most cases of IVH are secondary, where an intracerebral hemorrhage (ICH) ruptures into the ventricle.\(^5\) Spontaneous ICH is the most common cause of IVH—approximately 40 to 45% have concomitant IVH—followed by 13 to 28% of aneurysmal subarachnoid hemorrhage (SAH) presenting with IVH.\(^5\) Other secondary etiologies include traumatic brain injury (TBI), arteriovenous malformation (AVM), venous sinus thrombosis, and moyamoya disease. Risk factors for IVH associated with spontaneous ICH include older age, higher baseline ICH volume, mean arterial pressure (MAP) above 120 mm Hg, and deep subcortical location of the primary hematoma in close proximity to ventricles.\(^6\) Primary IVH, defined as a nontraumatic intracranial hemorrhage confined to the ventricular system and immediate parenchymal ependymal lining, is a rare and less well-understood neurological disease, and is a diagnosis of exclusion.\(^7\) These lesions, with a reported incidence of 3 to 7%, should be investigated with cerebral angiography to rule out structural pathology such as choroid plexus AVM and may have a higher risk of ventricular rehemorrhage with intraventricular fibrinolytic (IVF) therapy compared with secondary IVH. Dural AVMs can also rarely present with primary IVH presumably due to retrograde venous drainage creating backflow into subependymal veins causing their rupture.\(^8\) Any vascular or mass lesion defined on neuroimaging as the cause of IVH should be considered a contraindication to IVF with exception of a secured intracranial aneurysm.\(^9\)

ICH is a deadly form of stroke, with 30-day mortality rates of 35 to 52%.\(^4,10\) The addition of IVH to ICH is a well-established independent predictor of increased mortality, with estimates ranging from 50 to 80%.\(^4,6,10–13\) In a seminal prospective study of 129 ICH patients, those who demonstrated IVH (n = 47) had a 30-day mortality of 43%, a rate independently related to IVH volume on multivariate analysis.\(^13\) Similarly, Hallevi et al found that 45% of 406 ICH patients demonstrated IVH, and were more than two times as likely to have death or disability compared with ICH patients without IVH.\(^14\) Functionally, IVH is associated with significantly worse scoring on indices of health-related quality of life, with specific deficits in mobility, self-care, and activities of daily living in survivors.\(^15\)

Incidence rates of ICH/IVH are increasing with the aging population and the increased prescription of anticoagulation and antithrombotic medications, for a variety of indications.\(^10\) Patients with anticoagulant-associated ICH more often demonstrate IVH extension than those without use of oral anticoagulation.\(^16\)

The pathophysiology of spontaneous IVH involves vessel rupture into the ventricle from parenchymal ICH through ventricular wall erosion under the parenchymal hemorrhage, and distention of regional subependymal vessels with some vessels occluded by thrombus.\(^17\) Ependymal erosion may be the primary event or may occur secondary to the presence of intraventricular blood. Small parenchymal hemorrhagic infarcts at the ventricular edge which presumably rupture through the ependyma have also been described.\(^18\) Pathologically, IVH causes neurologic injury via three major mechanisms:\(^19\)

1. Obstructive hydrocephalus.
2. Local damage to neighboring structures—including diencephalic structures such as the thalamus which are crucial for consciousness and cognition—by mechanisms of mechanical compression, infiltration of inflammatory mediators, and edema exacerbated by blood breakdown products.
3. The presence of blood breakdown products and inflammatory mediators within the cerebrospinal fluid (CSF) cisterns, causing inflammation and fibrosis at the level of CSF granulations, exacerbating nonobstructive hydrocephalus, and sometimes resulting in the need for long-term CSF diversion.

While typically presenting at the ictus of the injury, IVH may also be a delayed phenomenon. Maas and colleagues investigated the onset of delayed IVH (dIVH) in a prospective data cohort, reporting that 21% (23 of 112 patients) developed dIVH, 43% required a ventriculostomy, and this was an independent predictor of death and poor outcome.\(^20\) dIVH was associated with significantly greater ICH expansion and higher rates of craniotomy. Possible risk factors for dIVH included atrial fibrillation, higher rate of warfarin use and presenting INR, and hematoma location in the lentiform nucleus. Conversely, in another prospectively studied cohort, dIVH was noted in 14.5% (19 of 131 patients), but was not an independent predictor of death or disability once hematoma expansion was controlled for in multivariate analysis.\(^21\) In a pooled analysis of the 1,310 ICH patients recruited into the INTERACT clinical trials, 107 demonstrated dIVH, which again was an independent predictor of poor outcome in patients with small and moderate sized ICH.\(^22\) dIVH was associated with vitamin K antagonist use, ICH volume, ICH growth, and higher NIH stroke scale score on presentation.\(^22\) The significance of dIVH for intraventricular thrombolytic therapy is that it may represent patients with greater risk of IVH reexpansion or a need for a longer pretreatment stabilization period. In the first 300 patients enrolled in the landmark CLEAR III trial (the results of which are discussed extensively later in this review), time from diagnostic CT to last IVH expansion was a median of 5.6 hours with range of 1.5 to 50.5 hours indicating that hemorrhage stability may require an individualized approach with serial CT based on risk factor assessment when applying interventional treatments to ICH.\(^23\)

Quantification of IVH: Bedside Scoring Tools with Clinical Utility

The simple presence of blood within the ventricles can have prognostic consequences. It is included as a variable in the ICH score, which predicts 30-day mortality after ICH.\(^24\) in the modified Fisher score which predicts vasospasm after SAH,\(^25,26\) and in TBI, where the presence of IVH on CT after TBI was associated with diffuse axonal injury as an independent predictor in a prospective study of 140 TBI patients.\(^27\)

Although the volume of a parenchymal clot can be approximated to the volume of a cylinder using the ABC/2
paradigm, the configuration and anatomy of the ventricles do not allow for such an approximation. Nevertheless, several investigators have attempted to quantify the amount of blood within the ventricles, in the absence of computerized volumetric analyses, by assigning a score to each ventricular compartment on CT scan, and correlating the score to clinical outcomes.

The Graeb score, initially described by Graeb and colleagues in 1982, is a semiquantitative score which ranges from 0 to 12. A maximum score of 4 is assigned to each of the right and left lateral ventricles, if there is blood filling the ventricle and is accompanied by ventricular expansion. The third and fourth ventricles are ascribed a maximum score of 2 each for being filled and expanded. Morgan and colleagues (2013) suggested, however, that the original Graeb score lacked the ability to differentiate specific regions of the ventricular system, and thus was unable to recapitulate true IVH volume. They instead formulated the modified Graeb score (mGS), where scores are assigned to specific ventricular compartments, that is, a maximum score of 4 is ascribed to each of the right, left, third, and fourth ventricles, in addition to a maximum score of 2 to each right and left temporal horn and each right and left occipital horn (Fig. 1). An additional point of 1 is given to each compartment if it is expanded beyond its normal anatomic limits due to hematoma, for a maximum score of 32. Both the Graeb and mGS scores have been extensively validated in outcome studies. The mGS has been validated in ICH patients from both clinical trials and a consecutive hospital-based study. From the CLEAR IVH trial (phase II) and the Virtual International Stroke Trials Archive (VISTA) with more than 400 participants, mGS was predictive of poor outcome (modified Rankin scale [mRS] > 3), whereas the original Graeb score was not. The strength of the mGS to predict outcome in IVH patients was also assessed in the Lund stroke registry, where 198 ICH patients were evaluated, 86 of whom had IVH. Each point increase in mGS increased the odds for a poor 90-day functional outcome (mRS > 3) by 11%, comparing favorably with a 12% increase in the odds of a poor outcome for each point increase from aforementioned clinical trial data. The mGS therefore applies as an independent predictor of death or poor functional outcome in both research and nonselected IVH populations.

Another score, proposed in 2009 by Hallevi and colleagues, termed the IVH score, is calculated as follows: each lateral ventricle score 0 (no blood or small amount of layering), 1 (up to one-third filled with blood), 2 (one-third to two-thirds filled with blood), or 3 (mostly or completely filled with blood)—for a total of 6 maximal points. The third and fourth ventricles score 0 for no blood or 1 if partially or completely filled with blood. Hydrocephalus is coded as present (1) or absent (0), for a potential total score of 9. This score demonstrated excellent correlation with software-derived IVH volumes in a retrospective analysis of 175 cases. Furthermore, total volume, consisting of IVH score and ICH volume using the ABC/2 estimation, was able to predict mortality and poor outcome with greater sensitivity and specificity than either the original Graeb score or ICH score alone.

Therefore, although software-based volumetric analysis of IVH has become the standard in clinical trials, simple bedside estimation of IVH severity has proven useful for early prognostication and evaluation of clot resolution with therapeutic removal.

Medical and Surgical Management of Spontaneous IVH Prior to Thrombolytic Therapy

The presence of IVH is one of the several indicators that a patient requires intensive care unit (ICU) level care, based on the Triage ICH model. The presence of IVH was a predictor of ICU admission and for ICU stay longer than 5 days in the INTERACT2 trial for intensive blood pressure (BP) management in ICH. Additionally, there are secondary complications that have been associated with IVH, such as an increased rate of nosocomial infection.

Our current care for IVH is predominantly driven by management guidelines for spontaneous ICH as published by the American Heart Association (AHA) and European Stroke guidelines and involves brain monitoring and ICU support in the setting of gradually accumulating evidence for primary clot (ICH) reduction.

Blood pressure management has been the mainstay of therapy for acute spontaneous ICH, with the goal of limiting hematoma expansion. The CLEAR III trial required BP stability according to AHA guidelines in the 6-hour period prior to start of intraventricular study agent. Current guidelines for BP control for ICH patients recommends (Class 1/Level of Evidence A) lowering systolic BP to 140 mm Hg, provided there are no contraindications in patients with a presenting systolic BP of 150 to 220 mm Hg. It is important to recognize that this degree of BP reduction may be potentially harmful in a patient with IVH causing obstructive hydrocephalus and elevated ICP. Most (75%) patients in the INTERACT2 trial presented with mild to moderate size (<20 mL) hematomas and therefore maintaining adequate cerebral perfusion pressure (CPP) was less of a concern. Moreover, just as INTERACT2 showed no significant effect of intensive BP-lowering treatment on hematoma growth, it is not clear whether acute lowering of systolic BP has an effect on minimizing IVH growth. Pooled analysis of INTERACT1 and INTERACT2, where ICH
patients were randomized to goal systolic BP of <140 or <180 mm Hg, demonstrated no clear effect of aggressive BP control on IVH growth between groups.38 Adjusted mean IVH growth was nonsignificantly greater in patients with a mean achieved systolic BP ≥160 mm Hg over 24 hours. Risk factors for IVH growth (>2 mL) in the first 24 hours in the FAST trial (recombinant activated factor VII [rFVIIa]) did, however, include baseline MAP greater than 120 mm Hg, along with larger baseline ICH volume.9 From these studies, it is reasonable to maintain a systolic BP <160 mm Hg during thrombolytic treatment, provided that CPP (MAP minus ICP) is preserved. AHA guidelines currently recommend a CPP of 50 to 70 mm Hg in patients undergoing ICP monitoring, depending on the status of cerebral autoregulation (Class IIb; Level of Evidence C).39 Analysis of CPP data from the CLEAR III trial suggests that maintaining MAP at the top end of this range may be associated with improved survival (Ziai W, MD, MPH, unpublished data, February 2017).

Prior to consideration of intraventricular thrombolysis, the decision for extraventricular drain (EVD) placement is made. Most often performed at the bedside, the EVD can relieve elevated ICP, evacuate intraventricular blood and blood breakdown products that may cause chemical meningitis,39 and is associated with decreased short-term mortality.40 EVD placement has never been subjected to a randomized controlled trial (RCT) for spontaneous IVH and remains controversial regarding indications for use and outcomes benefit, likely due to the multifactorial mechanisms of brain injury.41 AHA guidelines suggest that the use of an EVD is reasonable, especially in patients with decreased level of consciousness (Class IIa/Level of Evidence B).36

While EVDs are common practice, the threshold (both clinically and radiographically) for EVD insertion after IVH varies considerably. Generally, the presence of hydrocephalus (radiographically) and a deteriorating neurologic examination are indications for placing an EVD. From a retrospective analysis of 563 patients with spontaneous ICH and 25.2% of EVD use, the odds of EVD use increased for IVH growth (>2 mL) in the first 24 hours in the FAST trial (recombinant activated factor VII [rFVIIa]) did, however, include baseline MAP greater than 120 mm Hg, along with larger baseline ICH volume. From a retrospective analysis of 227 patients with IVH requiring clot removal, hydrocephalus, and in 41% developed at least one temporary occlusion. In a retrospective analysis of 227 patients with IVH requiring EVD, large bore catheters decreased the risk of catheter obstruction without any increase in catheter-related hemorrhages, and a nonsignificant decrease in catheter-related infections was also noted. Despite this, mortality was higher in the large bore catheter group, likely due to a selection bias where patients with larger volume hematomas were selected to receive the large bore catheters.

Over the past 20 years, there has been significant interest in the use of IVF to facilitate blood removal and maintain EVD patency. Experimental studies of thrombolytic-mediated clot removal have consistently demonstrated improved blood clot removal, hydrocephalus, and inflammation.45,46,48–51 In 2000, a systematic review of 16 retrospective studies (n = 201) with severe IVH (Graeb score ≥7) secondary to ICH reported that combined therapy with EVD placement and IVF was associated with a significantly lower mortality rate (9%) and lower risk for unfavorable outcome (22%), as compared with patients treated with EVD alone (mortality 56%; poor outcome: 87%).40 In 2002, a Cochrane database systematic review of 10 independent studies (8 case series/retrospective studies, 1 quasi–RCT, 1 RCT) using IVF found anecdotal evidence supporting safety and possible therapeutic value.52 Nearly a decade later, a systematic review of four randomized and eight observational studies comparing EVD alone to EVD combined with IVF in severe IVH due to spontaneous supratentorial ICH reported overall mortality risk decreased from 46.7% (EVD alone) to 22.7% (EVD + IVF).53 IVF was also associated with an increase in good functional outcome and with no significant difference between the two groups in terms of shunt dependence or complications, although the rebleeding rate was greater in
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Condition</th>
<th>Total patients</th>
<th>Number receiving IVF</th>
<th>Age (y)</th>
<th>ICH restriction</th>
<th>IVH volume requirement</th>
<th>Dose of fibrinolytic</th>
<th>Exclusion criteria</th>
<th>Other inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kramer et al9</td>
<td>Randomized clinical trial</td>
<td>aSAH</td>
<td>12</td>
<td>6</td>
<td>&gt;18</td>
<td>N/A</td>
<td>Presence/Absence</td>
<td>2 mg (Cathflo) q12h, for a max of 5 doses (10 mg total)</td>
<td>Aneurysm not completely secured; Uncorrected coagulopathy (INR &gt;1.5, PTT &gt;45, platelets &lt;50,000 IU/mm³; active extracranial hemorrhage</td>
<td>Modified Fisher’s score 4 (cisternal blood &gt;3 mm thick with IVH); routine EVD placement; CT scan after coil embolization and EVD insertion demonstrating stability; Study drug could be administered within 72 h of SAH</td>
</tr>
<tr>
<td>Ziai et al72</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>24</td>
<td>12</td>
<td>&gt;18</td>
<td>Supratentorial ICH with volume &lt;30 mL (by ABC/2 method)</td>
<td>IVH causing obstructive hydrocephalus requiring EVD</td>
<td>Randomized 1:1 (n = 16) to IVR alteplase at 0.3 or 1.0 mg q12h (CLEAR A) or 1.0 mg q12h or q8h (n = 36) (CLEAR B)</td>
<td>Posterior fossa ICH; structural cause of IVH (excluded by appropriate diagnostic studies); any severe complicating illness; active internal bleeding, coagulopathy with PT or PTT outside of normal range, platelet count &lt;75 IU/mm³</td>
<td>EVD inserted and a CT scan obtained at least 6 h later showed no significant new occurrence or increase in size of any hematoma and the 1st dose of tPA could be given within 48 h of the diagnostic head CT</td>
</tr>
<tr>
<td>Litrico et al39</td>
<td>Randomized clinical trial</td>
<td>aSAH</td>
<td>19</td>
<td>11</td>
<td>&gt;18</td>
<td>N/A</td>
<td>Severe IVH (Graeb score &gt;6) with 3rd and 4th ventricle obstructions</td>
<td>3 mg rt-PA q12h until 3rd and 4th ventricles were cleared from blood or to maximum total rt-PA dose of 36 mg, i.e., 12 doses</td>
<td>Coagulopathies (from iatrogenic or metabolic cause), or if not able to begin IVF within the first 48 h after onset of symptoms</td>
<td>Only one saccular and totally secured (coiling or clipping) aneurysm and EVD with proper placement were included and randomized according to the study’s protocol</td>
</tr>
<tr>
<td>Naff et al54</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>48</td>
<td>26</td>
<td>18–75</td>
<td>Supra-tentorial ICH (&lt;30 mL)</td>
<td>Massive IVH requiring EVD for treatment of obstructive hydrocephalus</td>
<td>3 mg rt-PA q12h until CT shows minimum of opening of third and fourth ventricles or until a safety end point (symptomatic bleeding, infection, or death)</td>
<td>Exclusion criteria included infratentorial bleeding, radiological evidence of structural lesion as source of ICH and evidence of</td>
<td>Randomized within 24 h of diagnostic CT showing IVH. A CT scan was required after EVD placement to demonstrate clot stability and proper EVD placement</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Condition</th>
<th>Total patients</th>
<th>Number receiving IVF</th>
<th>Age (y)</th>
<th>ICH restriction</th>
<th>IVH volume requirement</th>
<th>Dose of fibrinolytic</th>
<th>Exclusion criteria</th>
<th>Other inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naff et al&lt;sup&gt;99&lt;/sup&gt;</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>12</td>
<td>7</td>
<td>&gt;18</td>
<td>Supratentorial ICH (&lt;30 mL)</td>
<td>Required EVD for obstructive hydrocephalus</td>
<td>Urokinase 25,000 IU q12h until EVD removed by prespecified criteria, i.e., tolerated 24 h clamping</td>
<td>coagulopathy (INR &gt;1.7; platelet count &lt;100,000)</td>
<td>All hemorrhages were related to hypertension. Informed consent was sought only after EVD had been instituted. Patients were enrolled within 24 h after the initial episode of hemorrhage</td>
</tr>
<tr>
<td>Naff et al&lt;sup&gt;100&lt;/sup&gt;</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>8</td>
<td>4</td>
<td>&gt;18</td>
<td>Supratentorial ICH</td>
<td>Required EVD for obstructive hydrocephalus</td>
<td>Urokinase (up to 25,000 IU) q12h</td>
<td>Suspected structural source of ICH had to be excluded by appropriate diagnostic studies</td>
<td>IVH with or without ICH within 48 h before admission. IVC was clinically required for treatment of obstructive hydrocephalus</td>
</tr>
<tr>
<td>Tung et al&lt;sup&gt;101&lt;/sup&gt;</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>21</td>
<td>10</td>
<td>61.5 (avg)</td>
<td>Supratentorial ICH &lt; 40 mL</td>
<td>IVH with hydrocephalus requiring EVD</td>
<td>Urokinase (50,000 IU) q12h for 4 d (8 doses total)</td>
<td>IVH secondary to structural lesion or brainstem hemorrhage</td>
<td>Bilateral EVDs placed</td>
</tr>
<tr>
<td>Akdemir et al&lt;sup&gt;102&lt;/sup&gt;</td>
<td>Randomized clinical trial</td>
<td>ICH</td>
<td>16</td>
<td>7</td>
<td>61.3 (avg)</td>
<td>N/A</td>
<td>Severe IVH requiring EVD</td>
<td>5,000 IU to 50,000 IU urokinase BID, ongoing until clear CSF was obtained</td>
<td>N/A</td>
<td>Patients with coagulopathy and aneurysm were included in control group</td>
</tr>
<tr>
<td>Varelas et al&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Prospective cohort studies</td>
<td>aSAH</td>
<td>20</td>
<td>10</td>
<td>52 (avg)</td>
<td>N/A</td>
<td>IVH and hydrocephalus requiring EVD</td>
<td>2 mg Activase q12 to 24 h until 3rd/4th ventricles cleared of blood</td>
<td>N/A</td>
<td>Prospective case control of DSA-confirmed aneurysmal SAH with IVH</td>
</tr>
<tr>
<td>Volbers et al&lt;sup&gt;73&lt;/sup&gt;</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>128</td>
<td>64</td>
<td>64 (avg)</td>
<td>Supratentorial ICH &lt; 40 mL</td>
<td>IVH and hydrocephalus requiring EVD</td>
<td>Until 7/2008, 4 mg rt-PA q12h up to a max dose of 20 mg. After 8/2008, 1 mg rt-PA, q8h, to max cumulative dose of 12 mg. Treatment</td>
<td>N/A</td>
<td>IVF had to start &lt;48 h after symptom onset. Included only spontaneous ICH due to hypertension or amyloid</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Condition</th>
<th>Total patients</th>
<th>Number receiving IVF</th>
<th>Age (y)</th>
<th>ICH restriction</th>
<th>IVH volume requirement</th>
<th>Dose of fibrinolytic</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramakrishna et al[20]</td>
<td>Retrospective cohort</td>
<td>aSAH</td>
<td>76</td>
<td>41</td>
<td>52 (avg)</td>
<td>N/A</td>
<td>Admission Hunt–Hess grade (\geq)3, and a modified Fisher's grade 4, SAH with hydrocephalus requiring EVD</td>
<td>5 mg rt-PA q24h, for 7 d</td>
<td>Coagulopathies (metabolic or iatrogenic), and aneurysms not treated within 48 h. Nonaneurysmal SAH excluded</td>
</tr>
<tr>
<td>Ducruet et al[71]</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>30</td>
<td>13</td>
<td>65.5 (avg)</td>
<td>Supra-tentorial ICH</td>
<td>IVH requiring EVD on admission</td>
<td>Until 1/2006, 3 mg rt-PA bid. After 1/2006, 1 mg rt-PA bid, until clearance of blood from 3rd/4th ventricles</td>
<td>IVH secondary to structural lesion</td>
</tr>
<tr>
<td>Torres et al[103]</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>28</td>
<td>14</td>
<td>18–70</td>
<td>ICH (&lt;) 30 mL</td>
<td>Moderate to severe IVH (Graeb 6)</td>
<td>10,000 IU of urokinase q12h, until Graeb's score (&lt;) 6</td>
<td>Clotting/bleeding disorders, untreated cerebral vascular malformations (aneurysms, AVM)</td>
</tr>
<tr>
<td>Huttner et al[104]</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>44</td>
<td>22</td>
<td>64 (median)</td>
<td>Primary hypertensive ganglionic supratentorial ICH</td>
<td>IVH causing occlusive hydrocephalus</td>
<td>Maximum dose of 20 mg rt-PA. When all ventricles affected, five 4-mg doses q12h if one EVD present. If bilateral EVDs, five 2-mg doses q12h in each EVD</td>
<td>Excluded patients with unfavorable prognosis, &quot;do not resuscitate/treat&quot; within 24 h and patients requiring EVD due to mass effect, and those with hematoma expansion (&gt;)33%</td>
</tr>
<tr>
<td>Findlay et al[61]</td>
<td>Retrospective cohort</td>
<td>SAH</td>
<td>30</td>
<td>21</td>
<td>54.6 (avg)</td>
<td>N/A</td>
<td>Hemorrhage into at least 3 ventricles with ventriculomegaly requiring EVD</td>
<td>Standard initial dose of 4 mg rt-PA. Daily CT scans and more injections of rt-PA (2–4 mg) depending on IVH remaining. Goal to open ventricular</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Condition</th>
<th>Total patients</th>
<th>Number receiving IVF</th>
<th>Age (y)</th>
<th>ICH restriction</th>
<th>IVH volume requirement</th>
<th>Dose of fibrinolytic</th>
<th>Exclusion criteria</th>
<th>Other inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coplin et al19</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>40</td>
<td>22</td>
<td>22–95</td>
<td>No cerebellar hematoma</td>
<td>IVH requiring EVD</td>
<td>10,000 IU urokinase q12h until the 3rd/4th ventricles cleared of blood on CT or until full recovery or death</td>
<td>pathways, restore normal ventricular size, maintain catheter patency</td>
<td>recovery based on clinical examination and CT scan</td>
</tr>
<tr>
<td>Rainov et al105</td>
<td>Retrospective cohort</td>
<td>ICH</td>
<td>21</td>
<td>16</td>
<td>51 (avg)</td>
<td>Severe CT-diagnosed ICH with predominantly IVH</td>
<td>IVH at least in lateral and 3rd ventricles</td>
<td>10,000 IU urokinase q12h until clearance of all 4 ventricles</td>
<td>N/A</td>
<td>Ictus occurred from 12 h to 3 d before hospital admission</td>
</tr>
<tr>
<td>Todo et al106</td>
<td>Retrospective cohort</td>
<td>ICH/SAH/Moyamoya</td>
<td>11</td>
<td>6</td>
<td>52 (avg)</td>
<td>IVH involving all chambers, with casting of 3rd and 4th ventricles</td>
<td>IVH requiring EVD</td>
<td>10,000–12,000 IU urokinase, once or twice daily until clearance of 3rd and 4th ventricles</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; avg, average; DSA, digital subtraction angiography; EVD, external ventricular drain; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; IVF, intraventricular fibrinolysis; IVR, intraventricular; SAH, subarachnoid hemorrhage; N/A, not available.
the IVF group (11.4 vs. 6.4% in the EVD alone group). The mortality benefit was highly significant with urokinase, but not with recombinant tissue-type plasminogen activator (tPA), a finding raising the question of whether therapeutic effect of thrombolysis may differ by choice of agent. That same year, the Phase I Intraventricular Hemorrhage Treatment Trial was published by Naff and colleagues, who randomized 48 patients to receive intraventricular alteplase or saline and reported an excellent safety profile while demonstrating some benefit in decreasing mortality.54

Staykov et al also performed a systematic review of 23 studies (1993–2010; n = 436).19 The mortality rate was 53% (n = 133) for EVD alone and 16% (n = 212) for EVD plus thrombolysis, compared with 71% (n = 91) in conservatively treated patients. Unfavorable outcome was higher in the IVF group compared with other systematic reviews (45 vs. 70% for EVD alone vs. 86% for conservative treatment) but again suggested significant potential relative benefit from IVF.

Finally, an updated systematic review including eight RCTs demonstrated consistent results of mortality reduction with IVF by nearly half (compared with EVD alone), increased odds of good functional outcome by 66%, and decreased rate with IVF by nearly half (compared with EVD alone), increased RCTs demonstrated consistent results of mortality reduction in decreasing mortality.55

Ventriculitis and rehemorrhage rates were not increased with IVF.

These reviews all promote IVF as an effective strategy to reduce mortality and improve functional outcome, without significant increase in complication rates. Unfortunately, most data in these reviews came from small randomized and nonrandomized prospective/retrospective studies with considerable heterogeneity among patient populations, dosing regimens, length of follow-up, and etiologies (including both ICH and SAH in some). The findings of these meta-analyses do, however, support real-world data. In a retrospective review using the National Inpatient sample, 34,044 patients with spontaneous IVH were identified, 3.3% of who received intraventricular alteplase. These patients demonstrated a significant decrease in in-hospital mortality and a trend toward favorable discharge (i.e., home or inpatient rehabilitation) compared with EVD alone, without a concomitant increase in meningitis, nor any difference in chronic shunt diversion procedures.56

Intraventricular alteplase has proven to be a safe intervention, not only in patients with IVH after ICH, but also in patients with IVH due to SAH.5,57 In a randomized placebo-controlled trial of intraventricular alteplase versus saline in 12 patients with modified Fisher scale 4 SAH who had undergone aneurysm embolization and EVD placement, no new ICH developed. This small proof of concept trial demonstrated a significant reduction in intraventricular blood without any difference in neurological outcome at 6 months (a secondary outcome).9

Patient Selection for Intraventricular Thrombolysis

To understand the selection of IVH subjects for intraventricular thrombolysis, it is worthwhile to consider the focused patient selection in CLEAR III and in prior research studies (Table 1). The CLEAR IVH trials restricted entry to patients younger than 80 years with spontaneous (hypertensive) ICH volume <30 mL; obstruction of the third and/or fourth ventricles presenting within 24 hours of symptom onset; and stability of ICH, IVH, and any EVD tract hemorrhage prior to 72 hours from diagnostic CT scan.54,58 Patients in other studies prior to CLEAR III all generally excluded IVH associated with pregnancy, significant coagulopathy, intracranial tumor, AVM, cerebellar/brainstem hematoma, or intracranial aneurysm (Table 1). Several small studies of IVF in IVH associated with aneurysmal SAH have shown promise for this therapy in patients with secured aneurysms.9,59–61

Results from the CLEAR III trial itself cannot be generalized to patients with large ICH (>30 mL) or unstable hematomas, baseline mRS >1, age >80 years, Glasgow Coma Scale of 3, or probable amyloid angiopathy. Reversal of warfarin-induced coagulopathy or thrombocytopenia was permitted in CLEAR III, although patients on novel anticoagulants (NOACs) were excluded.

Other potential treatment indications and issues either beyond the scope of the current evidence or undergoing further evaluation involve earliest time to safely start IVF, minimum and maximum IVH volume responding to therapy, how much blood needs to be removed, and application of concomitant therapeutic approaches along with IVF. With regard to time from ictus to time of IVF treatment, a CLEAR III subgroup analysis suggested a trend toward improved benefit from IVF in patients treated within 48 hours of ictus.58

Lessons from the CLEAR III Trial Results

The CLEAR III trial itself was a randomized, double-blinded, placebo-controlled, multicenter trial powered to establish the effectiveness of intraventricular alteplase for the treatment of IVH on functional outcome at 180 days, dichotomized as mRS 0 to 3 versus 4 to 6.58 Power to observe was predicated on 40% mortality and baseline poor outcome of 78%. Retention was excellent, with 6-month follow-up data available for 97.4% of patients. However, there was no statistically significant difference in good versus poor functional status at 180 days between the saline- and alteplase-treated groups: saline 45% versus alteplase 48%, a difference of 3.5% (p = 0.42) after adjustment for IVH volume and thalamic ICH location. While the primary outcome was neutral, there was a significant decrease in the odds of being dead at 180 days for the experimental group (alteplase 18% vs. saline 29%; hazard ratio: 0.60; 95% confidence interval [CI]: 0.41–0.86; p = 0.006), which came at the expense of a significantly greater proportion of patients with mRS 5 (i.e., bedbound) compared with the saline group (17 vs. 9%; p = 0.007). There was, however, no difference in proportion of vegetative patients measured by extended Glasgow Outcome Scale (3% in both groups), nor any difference in survivors in long-term facilities (alteplase 14% vs. saline 12%; p = 0.48).

Consistent with the previous trials, intraventricular alteplase was deemed to be safe, with a significantly lower rate of bacterial ventriculitis or serious adverse events when
compared with intraventricular saline. The rate of symptomatic bleeding was the same in both groups (2%). There was also a significant decrease in neurological, respiratory, and sudden deaths in the alteplase group, supporting the claim that intraventricular alteplase may correct life-threatening obstruction within the ventricular system.

In a planned post hoc analysis, patients with IVH volumes greater than 20 ml demonstrated a significant treatment effect of intraventricular alteplase, with a statistically significant increase in patients with good functional outcome (mRS: 0–3) at 180 days (odds ratio: 1.87, 95% CI: 1.02, 3.42). Furthermore, in those patients who achieved > 85% reduction in IVH volume, the primary outcome was significant for the alteplase-treated group after adjusting for confounders. Fig. 2 shows the planned secondary analysis relating 180-day mRS score to the amount of clot removal at the end of treatment in all participants, which shows that for any starting IVH volume, probability of good outcome increased with greater IVH volume reduction. Unfortunately, only 33% of the alteplase group reached the treatment endpoint of 80% IVH clot removal, a fact emphasizing the goal of successful treatment of obstructive hydrocephalus, manifested by radiographic clearance or “reopening” of the third and fourth ventricles on CT. This has often been used as the criterion for discontinuation of dosing in studies of IVF and was one of three stopping criteria in the CLEAR-IVH protocol. The other two criteria, 80% removal of IVH clot volume and removal of mass effect, were less well emphasized and are major considerations for a follow-up trial to CLEAR III.

While it is unlikely that CLEAR III will immediately propel the practice of delivering intraventricular alteplase to standard practice in the treatment of IVH, its post hoc analyses suggest that with optimal patient selection, IVF may be quite efficacious. That is, in patients with hypertensive IVH greater than 20 ml, early and aggressive clot removal, with a target of greater than 80% IVH clot reduction (rather than simply alleviating radiographic third and fourth ventricular obstruction) is a safe, life-saving practice that may contribute to enhancing the quality of life in survivors of this moribund disease. It is also worthwhile noting that failure of the CLEAR III trial to meet its primary outcome may be partially explained by better-than-expected outcomes in the control group which had their EVD flushed with saline every 8 hours, as compared with historical controls, for which flushing the ventriculostomy at regular intervals does not generally occur in routine practice. The proportion of saline-treated patients achieving a good functional outcome (mRS: 0–3) in CLEAR III was 45%, while the pretrial power analysis, based on previous data, estimated good functional outcome in only 22% of the control group, thus leaving the trial with too few high-severity patients enrolled, and inadequately powered, to resolve this narrow difference between alteplase- and saline-treated groups.

### Enhancing Clot Lysis and Removal

Several strategies to enhance IVH clot lysis and removal exist. One such strategy, in conjunction with IVF, is the placement of a second EVD in the contralateral lateral ventricle where typically the dominant IVH resides. Prior to the CLEAR III trial, two studies had evaluated the effect of bilateral EVDs on IVH clearance with IVF, with different conclusions. Staykov et al evaluated 27 patients with spontaneous basal ganglionic ICH <40 mL and obstructive IVH, comparing 13 patients treated through a single and 14 through bilateral EVDs with IVF. No difference was found in IVH clot resolution between the two groups—either as total IVH volume reduction or reduction within segmented lateral, third, or fourth ventricles. A trend toward higher incidence of ventriculitis in the bilateral EVD group was reported. In this study, initial median IVH volume was between 30 and 35 mL in each group. Conversely, in 14 patients from the CLEAR III trials with IVH > 40 ml, bilateral EVD use versus single EVD (n = 7 in each group) led to increased clot resolution, in the presence of both alteplase and saline, suggesting that multiple catheters may be an effective, safe strategy to achieve the 80% benchmark for the removal of IVH under conditions of large IVH (>40 mL) with casting and mass effect. These data are also supported by a small randomized study of 47 patients with severe IVH (Graeb score ≥ 5) who were randomized to placement of one or two EVDs and reported significantly faster drainage of IVH volume with two EVDs compared with one, together with IVF and no incidence of rehemorrhage or infection.

A second strategy to improve clot removal efficiency is EVD placement position. In a post hoc analysis of data from the CLEAR III trial, clinically meaningful 85% IVH volume reduction was independently associated with smaller IVH volume, younger age, and placement of ventricular drainage catheters ipsilateral to the dominant IVH volume, adjusting for alteplase treatment. It has therefore been proposed that while initial EVDs indicated for ICP control may be targeted away from the intraventricular clot to maximize CSF drainage, placement of a second EVD directly into the ventricular clot may be necessary to effectively reduce IVH volume with fibrinolytic.

Fibrinolysis after intraventricular alteplase demonstrates first-order kinetics, which is saturable. A higher dose may, in theory, increase IVH clearance. The dose of

![Fig. 2](image-url) Relationship between mRS 0–3 (good outcome) at 180 days and percent clot removed by starting intraventricular hemorrhage (IVH) volume as determined at stability prior to randomization.
intraventricular alteplase used in the CLEAR III trial was 1 mg (in 1 mL of saline), delivered every 8 hours. This was the product of dose-finding trials, where clot resolution rates were not dose dependent across doses of 0.3, 1, and 3 mg when looking at the total IVH clearance (all ventricles together). Clearance of the third and fourth ventricle, however, did demonstrate a dose-dependent relationship. In the Phase I CLEAR IVH trial, a dose of 3 mg every 12 hours was also associated with a nonsignificantly higher symptomatic rehemorrhage rate which has not been observed with lower doses. Experimentally, higher doses of intraventricular alteplase have led to increased intraventricular leukocytosis and edema of periventricular tissues and choroid plexus in both hemispheres in rat models of IVH. In a clinical report of increased perihematomal edema with intraventricular alteplase, Ducruet and colleagues used doses of 3 mg of alteplase, while others, who did not see significant increases in perihematomal edema, used a 1 mg dose.

At this time, individualized dosing for IVF has not been studied. Variations in response to IVF with alteplase is a subject of future research and has been identified in related cohorts with radiographic features and clot-related factors. Additionally, genetic factors modulating the response to intravenous alteplase for revascularization after acute ischemic stroke have been characterized, including Apo E2 phenotype, polymorphisms at loci of the factor XII gene, thrombin-activatable fibrinolysis inhibitor gene, interleukin 1B gene, and von Willebrand factor genes. Furthermore, the risk for hemorrhagic transformation with higher serum levels of matrix metalloproteinase-9, involved in the integrity of the blood–brain barrier, has been reported.

Another proposed method for more aggressive IVH clearance is the use of an EVD with fibrinolysis in combination with lumbar drainage. Together, it is postulated that clearance of blood from the ventricles and removal of inflammatory mediators may exacerbate hydrocephalus and CSF flow and absorption would be enhanced. This has been tested in an open label randomized trial of 30 patients which was stopped early after interim analysis demonstrated 43% of the control group requiring permanent CSF diversion compared with no patients undergoing combination therapy. There was no difference in functional outcome at 90 days (a secondary outcome), nor was there a significant difference in IVH clearance between control and experimental groups, as noted by the change in Graeb score (from 9 to 2) over 10 days in each group. The results of the recently completed EARLYdrain trial assessing outcomes after early lumbar CSF drainage in aneurysmal SAH may influence this practice in spontaneous IVH patients.

### Hydrocephalus and Intracranial Hypertension as Indications for Intraventricular Fibrinolysis

Hydrocephalus occurs in 20 to 40% of all IVH patients, although again, the clinical benefit of EVD is debated.
hydrocephalus than IVH alone due to iron overload, and that both anatomical and histological changes are reversible with deferoxamine, an iron chelator.94

Rebleeding and Intraventricular Fibrinolysis

The most feared complication of IVF is rebleeding. As a result, protocols demand demonstration of hematoma stability, correction of any coagulopathy, and exclusion of any vascular anomaly as a cause for bleeding. From the structured screening process used in the CLEAR III trial, of 10,538 consecutive IVH cases prospectively screened, 496 cases (4.7%) screened negative for underlying vascular lesion, met the inclusion criteria, and were enrolled in the trial; 1,205 cases (11.4%) were concurrently screened and excluded from the trial because of a demonstrated underlying vascular lesion.95 It is therefore recommended that all patients under consideration for IVF treatment undergo vascular neuroimaging to rule out underlying lesions which may increase hemorrhage risk. The low risk of symptomatic rebleeding in the CLEAR III trial (2% in each treatment groups) likely reflects a stringent stabilization practice which required all sources of bleeding (ICH, IVH, catheter tract) to be stable for 12 hours before starting IVF. In their review, Staykov et al found that rebleeding associated with IVF occurred in approximately 5% of cases but was often asymptomatic.19

As a result, the current 2015 AHA guidelines for the management of ICH patients suggest IVF appears safe, while acknowledging the efficacy and safety of this treatment strategy remain uncertain (Class IIb/Level of Evidence B).18

Beyond Intraventricular Fibrinolysis

In addition to EVD-based catheter evacuation of IVH, there has been considerable interest in surgical and microsurgical techniques for the removal of blood from the ventricles. The 2015 AHA guidelines state that the efficacy of endoscopic treatment of IVH is uncertain (Class IIb/Level of Evidence B);36 however, this may be changed in updated guidelines, as minimally invasive surgery has come to the forefront as a viable option for treating IVH. For example, Chen and colleagues have reported on their experience using minimally invasive endoscopic surgery for thalamic hemorages with IVH and hydrocephalus in 48 patients which demonstrated a shorter length of stay and reduced need for ventriculoperitoneal (VP) shunting. However, there was no significant difference in mortality or functional outcomes at 30 and 90 days.96 Prior to this study, a trial in 2007 randomized 44 patients with IVH to management with EVD with IVF using urokinase or to endoscopic evacuation, with IVF utilized if the IVH volume was greater than 10 mL. The authors reported no statistical difference in mortality but a significant improvement in functional outcome at 2 months in the neuroendoscopy group.97 A meta-analysis comparing neuroendoscopic surgery combined with EVD for IVH versus the combination of EVD and IVF, which included 680 patients, noted significant benefits in mortality, good functional outcome, hematoma evacuation rate, and VP shunt dependence,98 suggesting that the use of endoscopic techniques with EVD may be a feasible option in the future.

Conclusions

IVH contributes significantly to the morbidity and mortality of ICH. The pathophysiological mechanisms include acute obstructive hydrocephalus, which can lead to sudden death, in addition to increased ICP and inflammation. The standard of care for the management of IVH causing obstructive hydrocephalus remains placement of an EVD for CSF diversion and ICP control. The insertion of an EVD may be lifesaving in the acute setting to relieve obstructive hydrocephalus; however, ICP crisis is not common among IVH patients, and routine EVD placement for CSF drainage is not sufficient for the clearance of intraventricular blood in a manner that is clinically beneficial.

Intraventricular thrombolysis with alteplase, at a dose of 1 mg every 8 hours, is safe, and may have beneficial effects on outcome in patients with a significant burden of intraventricular blood (i.e., >20 mL), if treatment is successful in removing >80% of IVH. Such treatment, in turn, is postulated to decrease inflammation and subsequent fibrosis within the ependymal and subarachnoid membranes. Other methods of efficient blood removal from the ventricles include use of lumbar drainage and microsurgical techniques, which have shown promise in the evacuation of large collections of intraventricular blood and may gain favor as more data become available.

Disclosures

• Peter Abdelmalik: No relevant financial disclosures.
• Wendy Ziai: Supported by grants SU01NS062851 and U01NS08082.

References

7 Sanders E. A study of primary, immediate, or direct hemorrhage into the ventricles of the brain. Am J Med Sci 1881;82:85–128
9 Kramer AH, Roberts DJ, Holodinsky J, et al. Intraventricular tissue plasminogen activator in subarachnoid hemorrhage patients: a
Spontaneous Intraventricular Hemorrhage  Abdelmalik, Ziai  757

prospective, randomized, placebo-controlled pilot trial. Neurocrit Care 2014;21(02):275–284
17 Gordon A. Primary ventricular hemorrhage: further contribution to a characteristic symptom group. Arch Neurol Psychiatry 1938;39:1272–1276

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


67 Ziai W, Awad I, Hanley D. Efficiency of intraventricular hemor-
rehage removal in the clot lysis: evaluation of Accelerated Resolu-
tion of Intraventricular Hemorrhage Trial (CLEAR III). In: Abstract Number: A502–020. 3rd European Stroke Organization Conference (ESOC 2017), Prague, Czech; 2017


Seminars in Respiratory and Critical Care Medicine Vol. 38 No. 6/2017